Tags

Type your tag names separated by a space and hit enter

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Neurology 2002; 58(9):1404-7Neur

Abstract

The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to investigate safety, tolerability, and efficacy of oral Delta(9)-Tetrahydrocannabinol (THC) and Cannabis sativa plant extract. Both drugs were safe, but adverse events were more common with plant-extract treatment. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant's global impression.

Authors+Show Affiliations

Department of Neurology, VU Medical Center, Amsterdam, the Netherlands. J.Killestein@vumc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12011290

Citation

Killestein, J, et al. "Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS." Neurology, vol. 58, no. 9, 2002, pp. 1404-7.
Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404-7.
Killestein, J., Hoogervorst, E. L., Reif, M., Kalkers, N. F., Van Loenen, A. C., Staats, P. G., ... Polman, C. H. (2002). Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 58(9), pp. 1404-7.
Killestein J, et al. Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS. Neurology. 2002 May 14;58(9):1404-7. PubMed PMID: 12011290.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety, tolerability, and efficacy of orally administered cannabinoids in MS. AU - Killestein,J, AU - Hoogervorst,E L J, AU - Reif,M, AU - Kalkers,N F, AU - Van Loenen,A C, AU - Staats,P G M, AU - Gorter,R W, AU - Uitdehaag,B M J, AU - Polman,C H, PY - 2002/5/16/pubmed PY - 2002/5/25/medline PY - 2002/5/16/entrez SP - 1404 EP - 7 JF - Neurology JO - Neurology VL - 58 IS - 9 N2 - The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to investigate safety, tolerability, and efficacy of oral Delta(9)-Tetrahydrocannabinol (THC) and Cannabis sativa plant extract. Both drugs were safe, but adverse events were more common with plant-extract treatment. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant's global impression. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/12011290/Safety_tolerability_and_efficacy_of_orally_administered_cannabinoids_in_MS_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12011290 DB - PRIME DP - Unbound Medicine ER -